Modelle Anti 21 tablets — Made in Croatia — Free Delivery

Brand: Pliva Hrvatska d.o.o.
Product Code: Modelle Anti
Availability: In Stock

$23.03

Description

Indications

Oral contraception.

Application

The tablet is removed from the blister pack in the place corresponding to the indicated day of the week, and swallowed without chewing, if necessary with a small amount of liquid. tablets are taken daily, the order of taking the tablets is in accordance with the direction of the index arrow.

Doses

The preparation is taken daily, 1 tablet per day at the same time (mainly in the evening), for 21 days. After this 21-day intake, a break (hormone-free interval) is taken for 7 days. Usually, menstrual-like withdrawal bleeding occurs 2 to 4 days after taking the last pill. After a 7-day break, regardless of whether the bleeding has ended, you should resume taking Modell Anti tablets from the next blister.

Start of preparation use

Hormonal contraceptives were not used in the previous period (last month). Taking pills starts from the 1st day of the cycle (1st day of menstrual bleeding). The contraceptive effect occurs on the 1st day of the preparation and continues during the 7-day hormone-free interval. You can start taking it from the 2-5th day of the cycle, regardless of whether the bleeding has ended. In this case, it is recommended to additionally use mechanical (barrier) methods of contraception during the first 7 days of taking the preparation (rule "7 days").

If menstruation began more than 5 days earlier, then the woman is advised to wait for the next period of menstruation to start taking the preparation.

Switching from another hormonal contraceptive to Modell Anti

Switching from another hormonal contraceptive with a 22- or 21-day regimen. All tablets from the previous package of the preparation should be taken in accordance with the instructions. After that, the first tablet should be taken the next day, without interruption in taking the tablets. It is not necessary to wait for the next menstrual period to begin. Additional use of contraceptives is not necessary.

Switching from another combined oral contraceptive (COC) for daily use (28-day regimen). You should start taking Modell Anti tablets after taking the last active tablet of the previous PDA (that is, after taking the 21st or 22nd tablet), without interruption in taking the tablets. The first Modell Anti tablet should be taken the next day. It is not necessary to wait for the next menstrual period to begin. Additional use of contraceptives is not necessary.

Switching from a progesterone-only contraceptive (POP or mini-pill). The first tablet of Modell Anti is taken the next day after stopping the mini-pill. However, in this case, additional contraception should be used during the first 7 days.

Switching from contraceptive hormonal injections or an implant. The first tablet of Modell Anti is taken on the day of implant removal or on the day on which the next injection is scheduled. However, additional contraception should be used for the next 7 days.

After a miscarriage or abortion

Taking the preparation Modell Anti can be started immediately after a miscarriage or abortion in the first trimester of pregnancy. In this case, additional methods of contraception are not required.

After childbirth

After childbirth, women who are not breastfeeding can start taking the preparation on the 21st-28th day of the postpartum period. In this case, the use of additional contraception is not required.

If the preparation is started later than 28 days after birth, additional contraceptive measures must be used during the first 7 days. However, if a woman has had sexual intercourse, then before starting the use of the preparation, pregnancy should be excluded or wait until the next menstrual period.

After canceling the application of Modell Anti

The start of the next menstrual cycle may be delayed by 1 week after the cancellation of Modell Anti.

Irregular pill intake

If a woman forgot to take a pill in a timely manner, the missed pill should be taken within 12 hours. In this case, no additional contraceptive measures are required, and Modell Anti tablets can be continued as usual. If more than 12 hours have passed between doses, contraceptive protection may decrease. You should immediately take the last missed tablet, and take the rest of the tablets as usual. In addition, the use of additional mechanical contraceptives, such as condoms, is required for the next 7 days. If there are less than 7 tablets left in the current package, the next package of Model Anti should be started as soon as the tablets in the current package run out, that is, a 7-day break (hormonal-free interval) should not be done (rule "7 days"). It is unlikely that a woman will experience withdrawal bleeding before she has finished taking all the pills in the second pack, although spotting or breakthrough bleeding may occur while taking the pills.

If withdrawal bleeding does not start after the end of the second pack of tablets, a pregnancy test should be done.

If vomiting or severe diarrhea occurs within 3-4 hours after taking the preparation, then the absorption of the preparation may be incomplete and reliable contraceptive protection is not provided. In this case, you should follow the instructions outlined in the subsection "Irregular pill intake". The preparation should be continued. However, during the remaining days of the cycle, additional mechanical methods of contraception must be used.

Contraindications

Do not take the preparation or you should immediately stop using it in such conditions:

hypersensitivity to active substances or any of the auxiliary components of the preparation;

presence or high risk of venous thromboembolism (VTE):

VTE in the presence (with the use of anticoagulants) or in history (deep vein thrombosis, pulmonary embolism - PLA);
hereditary or acquired predisposition to VTE, eg resistance to activated protein C (APC), including factor Leiden V, antithrombin III deficiency, protein C deficiency, protein S deficiency;

major surgery with prolonged immobilization;

high risk of VTE due to the presence of multiple risk factors (see SPECIAL INSTRUCTIONS);

presence or high risk of arterial thromboembolism (ATE):

ATE in the presence or history (for example, myocardial infarction) or a prodromal condition (in particular, angina pectoris);

cerebrovascular accident in the presence, history or prodromal condition (for example, transient ischemic attack - TIA);
hereditary or acquired tendency to ATE, such as hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
migraine with a history of focal neurological symptoms;

high risk of ATE due to the presence of multiple risk factors (see SPECIAL INSTRUCTIONS), such as:

diabetes mellitus with vascular complications;
severe hypertension;
severe dyslipoproteinemia;
uncontrolled diabetes mellitus;
hepatitis, jaundice, abnormal liver function (before normalization of liver function indicators);
generalized itching, cholestasis, especially in a previous pregnancy or during estrogen therapy;
history of gestational herpes;
inflammatory diseases of the female genital organs;
severe course of hypertension or severe hypertensive crisis;
Dubin-Johnson syndrome, Rotor syndrome, violation of the outflow of bile;
smoking at the age of 35;
a history of liver tumors (benign or malignant);
severe pain in the upper abdomen, an increase in the size of the liver, or symptoms of intra-abdominal bleeding;
exacerbation or newly diagnosed porphyria (all 3 forms, especially acquired porphyria);
hormonally sensitive tumors, such as tumors of the breast or uterus, present or in history;
pronounced disorders of lipid metabolism;
history of pancreatitis associated with severe hypertriglyceridemia;
the first signs of a migraine or more frequent than usual occurrence of a severe headache;
severe sensory impairments such as visual or hearing impairments;
impaired motor function (especially paresis);
severe depression;
otosclerosis during previous pregnancies;
amenorrhea of uncertain etiology;
endometrial hyperplasia;
bleeding from the external genital organs of unknown etiology;
increase in epileptic seizures;

Combined oral contraceptives containing EE are contraindicated for concomitant use with medicinal products containing ombitasvir/ritonavir and dasabuvir.

Compound

active ingredients: chlormadinone acetate and ethinyl estradiol; 1 tablet contains chlormadinone acetate 2 mg, ethinylestradiol 30 mcg;

excipients: lactose, corn starch, povidone, magnesium stearate,

hydroxypropyl methylcellulose, hydroxypropyl cellulose, talc, hydrogenated cottonseed oil, titanium dioxide (E171), iron oxide red (E 172).

Side effects

The most common (over 20%) side effects are breakthrough bleeding/spotting, headache, and chest pain.

The assessment of adverse reactions was carried out on the basis of the following classification of the frequency of their occurrence: very often (≥1/10); often (≥1/100–1/10); infrequently (≥1/1000–1/100); rarely (≥1/10,000–1/1000); very rarely (≥1 / 10,000), including isolated cases.

From the immune system: infrequently - hypersensitivity to the preparation, including allergic reactions.

On the part of the psyche: often - depressed mood, nervousness, irritability.

From the nervous system: often - dizziness, migraine (and / or its strengthening).

On the part of the organ of vision: often - visual impairment; rarely - conjunctivitis (for example, when using contact lenses), intolerance to contact lenses.

On the part of the organ of hearing and the labyrinth: very rarely - sudden hearing loss, tinnitus.

Since the cardiovascular system: rarely - collapse (acute vascular insufficiency), arterial hypotension, hypertension, varicose veins, VTE or ATE.

From the digestive tract: very often - nausea; often - vomiting; infrequently - abdominal pain, flatulence, diarrhea.

From the skin and subcutaneous tissue: often - acne; infrequently - a violation of pigment metabolism, chloasma (brown spots on the face), dry skin and hair loss; rarely - urticaria, eczema, erythema, itching, hirsutism, exacerbation of psoriasis, allergic skin reactions; very rarely - erythema nodosum.

From the musculoskeletal system: infrequently - back pain, heaviness in the muscles.

From the reproductive system and mammary glands: very often - vaginal discharge, dysmenorrhea (pain during the menstrual period), amenorrhea; often - pain in the lower abdomen; infrequently - vaginal candidiasis, galactorrhea, breast fibroadenoma, ovarian cysts; very rarely - breast enlargement, premenstrual syndrome, vulvovaginitis, menorrhagia.

Studies: often - increased blood pressure, weight gain; infrequently - hypertriglyceridemia.

General disorders: often - fatigue, swelling, heaviness in the limbs, weight gain; infrequently - increased sweating, loss of libido; rarely - increased appetite.

The following serious adverse events have been reported in women taking COCs:

The use of hormonal contraceptives is associated with an increased risk of thromboembolic diseases of the veins and arteries (for example, venous thrombosis, ELA, stroke, myocardial infarction). The risk of development may increase in the presence of additional factors (see SPECIAL INSTRUCTIONS).

With prolonged use of hormonal contraceptives, diseases of the biliary tract are more often detected.

In rare cases, after the use of hormonal contraceptives, benign, even more rarely, malignant neoplasms of the liver (liver tumors) occur, which sometimes leads to severe intra-abdominal bleeding.

Exacerbation of chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis).

The occurrence or worsening of conditions associated with the use of COCs: glucose tolerance, exacerbation of pancreatitis, cholestatic jaundice, exacerbation of herpes in pregnant women, otosclerosis.

You need to see a doctor if you experience pain in the upper abdomen. The preparation may need to be discontinued. The given symptom can in rare cases be observed with thrombosis of the hepatic veins or veins of the mesentery of the intestine.

Description of individual adverse reactions

The use of COCs is associated with an increased risk of developing thrombotic and thromboembolic diseases of the veins and arteries (such as stroke, myocardial infarction, TIA, venous thrombosis, ELA).

Overdose

In case of an overdose, nausea, vomiting are possible, and in the case of young girls, uterine bleeding. there are no specific antidotes. symptomatic treatment. it may be necessary, but only in rare cases, to monitor electrolyte levels, fluid balance and liver function.

Storage conditions

At a temperature not higher than 30 °C.

0 reviews

There are no reviews for this product.